Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study-Reference-Cited by-同舟云学术

Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study

Published:2015-03-31 Issue:6 Volume:20 Page:1051-1056
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kitayama Hiromitsu,Tsuji Yasushi,Sugiyama Junko,Doi Ayako,Kondo Tomohiro,Hirayama Michiaki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-015-0823-6.pdf

Reference19 articles.

1. Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227

2. Oo TH, Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2:196–201

3. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494

4. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference; Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Ann Oncol 17:20–28

5. Gralla RJ, Roila F, Tonato M et al (2013) Title of subordinate document. In: MASCC/ESMO antiemetic guideline 2013. Multinational Association of Supportive Care in Cancer. http://www.mascc.org/assets/Guidelines-Tools/mascc_guidlines_english_2014.pdf . Accessed Dec 2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology;International Journal of Clinical Oncology;2024-09-11

2. Defining the Clinical Benefits of Adding a Neurokinin-1 Receptor Antagonist to Control Chemotherapy-Induced Nausea and Vomiting in Moderately Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology;2024-08-19

3. Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): A single-center, single-blinded, randomized, controlled clinical trial;Frontiers in Pharmacology;2022-12-13

4. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis;The Oncologist;2022-04-15

5. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16